BetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2024
0mins
Source: Newsfilter
Genotoxicity Study Results: BetterLife Pharma Inc. announced successful completion of genotoxicity studies for its drug candidate BETR-001, showing no evidence of bone marrow toxicity or DNA mutation, which is crucial for FDA approval and clinical trials.
Company Developments: The company also issued shares and warrants related to convertible debentures, while continuing to develop BETR-001 and another compound, BETR-002, aimed at treating neuro-psychiatric disorders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
